Comprehensive genomic profiling has become a routine part of modern oncology, and a 148-gene next-generation sequencing (NGS) panel for solid tumors is designed to survey a broad set of cancer-relevant genes from a single specimen. Rather than testing one marker at a time, this approach sequences hundreds of regions in parallel and reports the alterations that may inform treatment, clinical-trial eligibility, or further diagnostic work-up. The service is built around a stated reporting window of roughly eight working days, which helps clinicians fit molecular results into an active treatment timeline.
NGS works by fragmenting DNA extracted from the tumor sample, attaching sequencing adaptors, and amplifying millions of short fragments simultaneously on a massively parallel platform. Each fragment is read independently, and dedicated bioinformatics software maps the resulting sequences back to a reference human genome. Because the process examines many DNA molecules at once, it can detect low-frequency variants that older single-gene methods might miss. For solid tumor profiling, the workflow typically begins with nucleic acid extraction from formalin-fixed, paraffin-embedded (FFPE) tissue or, in some cases, from a plasma-derived cell-free DNA sample when tissue is limited.
A panel of this size is constructed to cover multiple alteration classes, not just one. It can identify single-nucleotide variants, small insertions and deletions, copy-number changes, and select gene rearrangements or fusions. The gene list is usually weighted toward established and emerging drivers across major solid tumor types, along with genes whose status guides the use of targeted agents or immune-based strategies. The breadth matters because a patient's tumor may harbor more than one relevant alteration, and a wider net reduces the need for repeated biopsies to chase individual markers.
Raw sequence reads are only useful after careful interpretation. The laboratory filters variants by quality, annotates them against gene and protein databases, and classifies each finding by its expected clinical relevance. A transparent report will separate confirmed pathogenic or likely pathogenic alterations from variants of uncertain significance, and will note which findings map to approved or investigational therapies. This interpretive layer, not the sequencing alone, is what turns raw data into an actionable clinical document.
Q: Does a 148-gene panel replace a pathologist's review of the tumor? A: No. Histopathological examination and the molecular report are complementary; the panel adds genomic detail on top of the morphology already established by the pathology team.
Q: Can this test be run on a small biopsy? A: NGS is designed to work with limited input, including small FFPE cores, though very low tumor content can affect how many alterations are confidently called.
Q: Will the panel tell me which drug to prescribe? A: It surfaces genomic alterations linked to targeted or immune strategies, but therapy selection should always be made by the treating physician within approved labeling and guidelines.
Comprehensive genomic profiling has become a routine part of modern oncology, and a 148-gene next-generation sequencing (NGS) panel for solid tumors is designed to survey a broad set of cancer-relevant genes from a single specimen. Rather than testing one marker at a time, this approach sequences hundreds of regions in parallel and reports the alterations that may inform treatment, clinical-trial eligibility, or further diagnostic work-up. The service is built around a stated reporting window of roughly eight working days, which helps clinicians fit molecular results into an active treatment timeline.
NGS works by fragmenting DNA extracted from the tumor sample, attaching sequencing adaptors, and amplifying millions of short fragments simultaneously on a massively parallel platform. Each fragment is read independently, and dedicated bioinformatics software maps the resulting sequences back to a reference human genome. Because the process examines many DNA molecules at once, it can detect low-frequency variants that older single-gene methods might miss. For solid tumor profiling, the workflow typically begins with nucleic acid extraction from formalin-fixed, paraffin-embedded (FFPE) tissue or, in some cases, from a plasma-derived cell-free DNA sample when tissue is limited.
A panel of this size is constructed to cover multiple alteration classes, not just one. It can identify single-nucleotide variants, small insertions and deletions, copy-number changes, and select gene rearrangements or fusions. The gene list is usually weighted toward established and emerging drivers across major solid tumor types, along with genes whose status guides the use of targeted agents or immune-based strategies. The breadth matters because a patient's tumor may harbor more than one relevant alteration, and a wider net reduces the need for repeated biopsies to chase individual markers.
Raw sequence reads are only useful after careful interpretation. The laboratory filters variants by quality, annotates them against gene and protein databases, and classifies each finding by its expected clinical relevance. A transparent report will separate confirmed pathogenic or likely pathogenic alterations from variants of uncertain significance, and will note which findings map to approved or investigational therapies. This interpretive layer, not the sequencing alone, is what turns raw data into an actionable clinical document.
Q: Does a 148-gene panel replace a pathologist's review of the tumor? A: No. Histopathological examination and the molecular report are complementary; the panel adds genomic detail on top of the morphology already established by the pathology team.
Q: Can this test be run on a small biopsy? A: NGS is designed to work with limited input, including small FFPE cores, though very low tumor content can affect how many alterations are confidently called.
Q: Will the panel tell me which drug to prescribe? A: It surfaces genomic alterations linked to targeted or immune strategies, but therapy selection should always be made by the treating physician within approved labeling and guidelines.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
